Media headlines about Amedisys (NASDAQ:AMED) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amedisys earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the health services provider an impact score of 45.3964457297405 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Amedisys, Inc. – Value Analysis (NASDAQ:AMED) : September 15, 2017 (finance.yahoo.com)
- Amedisys Inc (AMED) Receives Buy Rating from Oppenheimer Holdings, Inc. (americanbankingnews.com)
- North America Home Healthcare Industry is poised to reach USD 124.11 billion by 2021 (reports.pr-inside.com)
- Amedisys Rides High on Strong Prospects Amid Margin Woes (finance.yahoo.com)
- Fresenius Medical Opens Manufacturing Plant in Malaysia (finance.yahoo.com)
Several research analysts have recently commented on AMED shares. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Friday. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Wednesday, July 26th. Finally, Bank of America Corporation started coverage on Amedisys in a research note on Monday, August 21st. They issued a “neutral” rating and a $55.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $56.44.
Shares of Amedisys (NASDAQ:AMED) traded down 1.42% during mid-day trading on Friday, reaching $52.03. The company had a trading volume of 454,262 shares. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 44.47 and a beta of 0.84. The stock has a 50 day moving average of $50.02 and a 200-day moving average of $54.86. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.42 EPS. On average, analysts expect that Amedisys will post $2.21 earnings per share for the current fiscal year.
In other news, Director Bruce D. Perkins bought 2,000 shares of Amedisys stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the completion of the acquisition, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Amedisys (AMED) Stock Price” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-amedisys-amed-stock-price.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.